A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with AnaplasticAstrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Sponsor: |
Orbus Therapeutics, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ9886 |
U.S. Govt. ID: |
NCT02796261 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during the study.
This study is closed
Investigator
Andrew Lassman, MD
Are you at least 18 years old? |
Yes |
No |
Have you been diagnosed with Anaplastic astrocytoma? |
Yes |
No |